---
schema_version: "secwatch.filing_event.v1"
accession: "0001503274-25-000074"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2025-07-18T23:59:59+00:00"
generated_at: "2026-05-18T05:39:26.768541+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Quanterix terminates Akoya executives post-acquisition; expects $2.8M annual savings, $3.3M severance cost

## Summary
- Terminating certain Akoya executives under its Executive Severance Plan as part of integration.
- Expects annualized cash savings of ~$2.8M from reduced costs and streamlined operations.
- Anticipates ~$3.3M in severance expenses, all cash expenditures, in 2025.
- Terminations part of plan to realize synergies from recently closed Akoya acquisition.

## SEC filing metadata
- accession: 0001503274-25-000074
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2025-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000074/0001503274-25-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000074/qtrx-20250714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001503274-25-000074
- JSON: https://secwatch.observer/filing/0001503274-25-000074.json
- Plain text: https://secwatch.observer/filing/0001503274-25-000074.txt

## Key facts
- Restructurings & Charges
  Quanterix Corp announced a restructuring with charges of approximately $3.3 million affecting Akoya Biosciences, Inc. (newly acquired subsidiary) (certain executives of the Company's newly acquired subsidiary, Akoya Biosciences, Inc.).
  - Type: restructuring
  - Charge: approximately $3.3 million
  - Affected area: Akoya Biosciences, Inc. (newly acquired subsidiary)
  - Headcount: certain executives of the Company's newly acquired subsidiary, Akoya Biosciences, Inc.
  source text: costs and streamlined operations and are expected to result in annualized cash savings of approximately $2.8 million. The Company expects to incur expenses of approximately $3.3 million, substantially all of which will be cash expenditures incurred in 2025 for severance required under Akoya’s Executive Severance Plan. The Company’s estimates are based on a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000074/0001503274-25-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.